Pharmaceutical company Incyte shows strong commercialization momentum, revenue surges 38% and raises full-year forecast
Biopharmaceutical company Incyte Corp (INCY) reported second-quarter financial results on Tuesday, showing that thanks to overall growth in its core products and one-time gains from a settlement with the government over the Opzelura rebate dispute, the company's revenue significantly exceeded expectations and it raised its full-year performance guidance. The financial report shows that Incyte’s total revenue in the second quarter reached US$1.67 billion, a year-on-year increase of 38%. Among them, total product net sales were US$1.49 billion, a year-on-year increase of 40%. Quarterly net profit was US$586 million, or US$2.81 per share; adjusted net profit was US$643 million, or US$3.09 per share, far exceeding market expectations of US$2.10. The quarter's results included a one-time non-cash gain of $246 million resulting from the company's settlement with the Centers for Medicare and Medicaid Services over Opzelura's rebate criteria and the reversal of related accruals. Excluding the impact of this revenue, total product net sales increased by 17% year-on-year. In terms of core product performance, the quarterly sales of the flagship product Jakafi and its new dosage form Jakafi XR were US$817 million, a year-on-year increase of 7%. Opzelura's sales performance was particularly strong, with quarterly net sales reaching US$450 million, a year-on-year surge of 173%. Among other products, Niktimvo contributed US$60 million, Monjuvi contributed US$54 million, and Zynyz contributed approximately US$50 million, all of which achieved considerable growth. Thanks to the strong performance, the company raised its full-year 2026 total net sales guidance to $5.13 billion to $5.26 billion from the previous range of $4.77 billion to $4.94 billion. In terms of business expansion and pipeline update, the company recently acquired Vega Therapeutics for US$1.25 billion and added a Phase III drug candidate targeting von Willebrand's disease to the pipeline. At the same time, the company decided to cease development of a Phase I JAK2V617F inhibitor to prioritize advancing next-generation pipeline assets. The company held $4.5 billion in cash and cash equivalents at the end of the quarter, providing financial flexibility for its subsequent development.